Key result
Circulating cell-free DNA rises ~6-fold in AMI and demonstrates strong diagnostic performance.
Why the study?
Circulating cell-free DNA has emerged as a potential biomarker for cardiovascular injury, but its clinical relevance in acute myocardial infarction remains underexplored.
Does circulating cell-free DNA (cfDNA) provide diagnostic utility and correlate with established cardiac biomarkers in patients with acute myocardial infarction?
Cross-Sectional (n=139)
Does circulating cell-free DNA (cfDNA) provide diagnostic utility and correlate with established cardiac biomarkers in patients with acute myocardial infarction?
Answers are grounded in this paper and cite their sources.
Circulating cell-free DNA demonstrates strong diagnostic accuracy for acute myocardial infarction, particularly in the late phase (18-24 hours), where it strongly correlates with hs-cTnT and NT-proBNP.
Circulating cell-free DNA (cfDNA) has emerged as a potential biomarker for cardiovascular injury, yet its clinical relevance in acute myocardial infarction (AMI) remains underexplored. cfDNA from 107 AMI patients and 32 healthy controls were isolated and its associations with clinical, demographic and biochemical profiling were explored. Patients were stratified by chest pain duration (0–24 h) to assess cross-sectional temporal trends. cfDNA levels showed six-fold elevation in AMI patients compared to controls and were associated with adverse cardiometabolic and lifestyle risk factors. cfDNA levels increased progressively with chest pain duration, peaking for 18–24 h (median:55.31 ng/mL), and strongly correlated with hs-cTnT (rho = 0.535) and NT-proBNP (rho = 0.615) during this phase. Overall diagnostic performance of cfDNA was good (AUC = 0.858), which further improved in late-phase AMI (AUC = 0.904). Strong diagnostic performance of cfDNA, particularly in the late phase AMI, suggests its potential as a complementary tool to existing cardiac biomarkers.
No takes yet. Share an insight, caveat, or question.
Mahajan et al. (2026) conducted a cross-sectional in Acute myocardial infarction (AMI) (n=139). Circulating cell-free DNA (cfDNA) vs. Healthy controls was evaluated on Diagnostic performance for acute myocardial infarction (AUC 0.858 (overall); AUC 0.904 (late-phase AMI)). Circulating cell-free DNA showed a 6-fold elevation in AMI vs controls and strong diagnostic performance (overall AUC 0.858; late-phase AUC 0.904).
Synapse has enriched 10 related papers. Consider them for comparative context: